實驗室成員
組長 林鴻清 醫師
聽力組
林鴻清 資深主治醫師
蔡循典 主治醫師
陳姵妤 主治醫師
褚嘉慧 主治醫師
語言組
謝麗君 資深主治醫師
王瀛標 資深主治醫師
研究人員
邱媚祺 陳思伶
研究主題
人工電子耳植入手術及術後聽語成效研究：(林鴻清、陳姵妤、褚嘉慧 醫師負責)
人工電子耳之硬體設備已購置完成，軟體之人員培訓亦已成熟。自1998年10月至今，本院林鴻清醫師已成功植入250例人工電子耳，已建立醫院之信譽。在術後的聽語成效研究上，再由陳姵妤醫師一起合作研究。
遺傳聽力醫學：（蔡循典 博士負責）
林鴻清醫師為臺灣新生兒聽力篩檢推手，且馬偕新生兒聽力篩檢成績執國內之牛耳。千分之一活產新生兒為重度先天性聽障，其中超過一半為遺傳成因，且為單一基因突變，聽障基因數目雖近百，但以連結素26佔最大宗。
語言科學研究組：(謝麗君 醫師負責)
主要研究方向為 (1)舌部超音波與聲學訊號；(2)建立中文語料鼻音分析之常模。
馬偕醫學院聽語學系暨研究所之設立與後續發展：(林鴻清、謝麗君、王瀛標醫師)
起初是由醫研部「聽力語言科學研究組」為班底創立馬偕醫學院聽語學系，連動馬偕醫院提供學校有完善之實習、研究環境。馬偕聽語系之充配研究人力資源，可以回饋馬偕紀念醫院之聽語服務，保有競爭力，以能永續發展。
代表著作
Chen PY, Tsai CY, Wu JL, Li YL, Wu CM, Chen KC, Hwang CF, Wu HP, Lin HC, Cheng YF, Lo MY, Liu TC, Yang TH, Chen PL, Hsu CJ, Wu CC. Hearing features and cochlear implantation outcomes in patients with pathogenic MYO15A variants: a multi-center observational study. Ear and Hearing 2022; 43(4):1198-1207. (SCIE, OTORHINOLARYNGOLOGY) (IF: 3.562, Ranking: 4/27=14.8%)
Hsu PY, Hsieh LC, Wang YH, Chen SJ, Chan YK, Shen KH, Wang YP. Olfactory outcomes after middle turbinate resection in endoscopic transsphenoidal surgery: a prospective randomized study. Otolaryngology-Head and Neck Surgery 2022; 167(6):964-970. (SCIE, OTORHINOLARYNGOLOGY) (IF: 5.591, Ranking: 3/43=6.9%)
Hsieh LC, Lee GS, Lee KS, Chang CW, Wang YP. Hypernasality after the endoscopic modified lothrop procedure for refractory frontal sinusitis. International Forum of Allergy and Rhinology 2021; 11(8):1260-1263. (SCIE, OTORHINOLARYNGOLOGY) (IF: 50.426, Ranking: 4/43=9.3%)
Tsai SC, Lin FC, Chang KH, Li MC, Chou RH, Huang MY, Chen YC, Kao CY, Cheng CC, Lin HC, Hsu YC. The intravenous administration of skin-derived mesenchymal stem cells ameliorates hearing loss and preserves cochlear hair cells in cisplatin-injected mice SMSCs ameliorate hearing loss and preserve outer hair cells in mice. Hearing Research 2022; 413:108254. (SCIE, OTORHINOLARYNGOLOGY, NEUROSCIENCES) (IF: 3.672, Ranking: 3/27=11.1%)
Lin YF, Lin HC, Tsai CL, Hsu YC. GJB2 mutation spectrum in the Taiwanese population and genotype-phenotype comparisons in patients with hearing loss carrying GJB2 c.109G>A and c.235delC mutations. Hearing Research 2022; 413:108135. (SCIE, OTORHINOLARYNGOLOGY, NEUROSCIENCES) (IF: 3.672, Ranking: 3/27=11.1%)
Lin CF, Wang MC, Merton AT, Ho NH, Wu PS, Hsu AT, Wang YP* Add-on effect of clarithromycin to oral steroids as post- operative therapy for chronic rhinosinusitis with nasal polyps: a randomised controlled trial. Rhinology 2020; 58(6):550-558. (SCIE, OTORHINOLARYNGOLOGY) (IF: 6.634, Ranking: 2/43=4.6%)
Hung TC, Liu TJ, Lu TM, Wang YP, Chen TL, Huang CC, Lai YC, Liu CL, Sun KH. Building a model to precisely target the responders of a novel intermittent negative air pressure device-with mechanism definition. Sleep Medicine 2020; 72:20-27. (SCIE, CLINICAL NEUROLOGY) (IF: 4.842, Ranking: 63/212=27.9%)
Lin KM, Lin SJ, Lin JH, Lin PY, Teng PL, Wu HE, Yeh TH, Wang YP, Chen MR, Tsai CH. Dysregulation of dual-specificity phosphatases by Epstein-Barr virus LMP1 and its impact on lymphoblastoid cell line survival. Journal of Virology 2020; 94(4):e01837-19. (SCIE, VIROLOGY) (IF: 6.549, Ranking: 11/37=29.7%)
Pan YA, Wang YP, Chen YC, Hsieh LC*. Changes of nasalance scores in patients with chronic rhinosinusitis. International Forum of Allergy and Rhinology 2021; 11(6):1022-1024. (SCIE, OTORHINOLARYNGOLOGY) (IF: 5.462, Ranking: 4/43=9.3%)
Chen CK, Hsieh LC*. Clinical outcome of exclusive endoscopic tympanoplasty with porcine small intestine submucosa in 72 patients. Clinical Otolaryngology 2020; 45(6):938-943. (SCIE, OTORHINOLARYNGOLOGY) (IF: 2.729, Ranking: 16/43=37.2%)
Chen CK, Chang KP, Chien CY, Hsieh LC*. Endoscopic transcanal removal of external auditory canal osteomas. Biomedical Journal 2021; 44(4):489-494. (SCIE, BIOCHEMISTRY & MOLECULAR BIOLOGY, MEDICINE, RESEARCH & EXPERIMENTAL) (IF: 7.892, Ranking: 47/296=15.9%)
Chen PY, Lin YH, Liu TC, Lin YH, Tseng LH, Yang TH, Chen PL, Wu CC, Hsu CJ. Prediction model for audiological outcomes in patients with GJB2 mutations. Ear and Hearing 2020; 41(1):143-149. (SCIE, OTORHINOLARYNGOLOGY) (IF: 3.562, Ranking: 4/27=14.8%)